QI
ATRA icon

QS Investors’s Atara Biotherapeutics ATRA Stock Holding History

QS Investors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$475K Buy
+1,220
New +$435K 0.01% 751

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

QS Investors's ATRA Position: Q2 2021 in Review

QS Investors opened a new position in Atara Biotherapeutics (ATRA) in Q2 2021: 1,220 shares worth $475K. The stake represents 0.01% of the portfolio and ranks #751 among its holdings.

145 funds tracked by Wall St. Rank hold ATRA as of Q2 2021.

  • QS Investors held 1,220 shares of Atara Biotherapeutics worth $475K as of Q2 2021.
  • Atara Biotherapeutics was a new QS Investors position in Q2 2021.
  • Atara Biotherapeutics made up 0.01% of QS Investors's portfolio in Q2 2021, its #751 holding.
  • 145 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.